Approaches, Progress, and Challenges to Hepatitis C Vaccine Development.
Approaches, Progress, and Challenges to Hepatitis C Vaccine Development.
复制标题
DOI:
10.1053/j.gastro.2018.08.060
复制
发表时间:
2019-01
期刊:
影响因子:
29.4
通讯作者:
Cox AL
中科院分区:
文献类型:
--
作者:
Bailey JR;Barnes E;Cox AL
Risk factors for hepatitis C virus (HCV) infection vary, and there were an estimated 1.75 million new cases worldwide in 2015. The World Health Organization aims for a 90% reduction in new HCV infections by 2030. An HCV vaccine would prevent transmission, regardless of risk factors, and significantly reduce the global burden of HCV-associated disease. Barriers to development include virus diversity, limited models for testing vaccines, and our incomplete understanding of protective immune responses. Although highly effective vaccines could prevent infection altogether, immune responses that increase the rate of HCV clearance and prevent chronic infection may be sufficient to reduce disease burden. Adjuvant envelope or core protein and virus-vectored nonstructural antigen vaccines have been tested in healthy volunteers who are not at risk for HCV infection; viral vectors encoding nonstructural proteins are the only vaccine strategy to be tested in at-risk individuals. Despite development challenges, a prophylactic vaccine is necessary for global control of HCV.
登录
查看更多内容
影响因子:
12.4
作者:
Capone, Stefania;Naddeo, Mariarosaria;Folgori, Antonella
通讯作者:
Folgori, Antonella
DOI:
10.1084/jem.20050121
发表时间:
2005-06-06
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
Cox AL;Mosbruger T;Mao Q;Liu Z;Wang XH;Yang HC;Sidney J;Sette A;Pardoll D;Thomas DL;Ray SC
通讯作者:
Ray SC
影响因子:
4.6
作者:
Christiansen D;Earnest-Silveira L;Chua B;Meuleman P;Boo I;Grubor-Bauk B;Jackson DC;Keck ZY;Foung SKH;Drummer HE;Gowans EJ;Torresi J
通讯作者:
Torresi J
影响因子:
8
作者:
Bailey, Justin R.;Flyak, Andrew I.;Crowe, James E., Jr.
通讯作者:
Crowe, James E., Jr.
影响因子:
5.4
作者:
Bassett, SE;Brasky, KM;Lanford, RE
通讯作者:
Lanford, RE